European Molecular Genetics Quality Network

European Molecular Genetics Quality Network
Name	European Molecular Genetics Quality Network
Formation	1996
Headquarters	Europe
Region served	International
Membership	Clinical laboratories
Leader title	Director

Contents

European Molecular Genetics Quality Network

The European Molecular Genetics Quality Network provides external quality assessment for clinical molecular genetics laboratories across Europe, engaging with institutions such as University College London, Charité – Universitätsmedizin Berlin, Karolinska Institutet, University of Oxford, Institut Pasteur, University of Paris, University of Copenhagen, University of Amsterdam, KU Leuven, University of Barcelona, and Sapienza University of Rome as participants and collaborators. It liaises with regulatory and standard-setting bodies including European Commission, European Directorate for the Quality of Medicines & HealthCare, World Health Organization, Council of Europe, European Medicines Agency, National Health Service (England), Federal Institute for Drugs and Medical Devices (BfArM), and national competent authorities in member states. The Network works alongside professional societies and organizations like European Society of Human Genetics, American College of Medical Genetics and Genomics, International Organization for Standardization, College of American Pathologists, Association for Clinical Genomic Science, and European Molecular Biology Laboratory to harmonize practice across clinical, academic, and commercial laboratories.

History

The Network originated in the mid-1990s amid growing demand for reliable diagnostics following advances at institutions such as Wellcome Trust Sanger Institute, Cold Spring Harbor Laboratory, Max Planck Society, Biotechnology and Biological Sciences Research Council, and Medical Research Council laboratories. Early collaborative meetings involved representatives from European Society of Human Genetics, World Health Organization Regional Office for Europe, European Commission Directorate-General for Health and Food Safety, Council of Europe, and national laboratory services like National Health Service (Scotland), Institut de microbiologie (Belgium), and Istituto Superiore di Sanità. Key milestones included expansion of proficiency testing programs to cover monogenic disorders, oncology markers, and pharmacogenetics paralleling discoveries at Human Genome Project centers and translational efforts at Memorial Sloan Kettering Cancer Center and Mayo Clinic. Over time the Network aligned its activities with standards from International Organization for Standardization, European Committee for Standardization, and accreditation models exemplified by Deutsche Akkreditierungsstelle and United Kingdom Accreditation Service.

The Network is organized with a secretariat, technical advisory groups, and working parties drawing experts from university hospitals such as Hôpital Necker–Enfants Malades, St. Thomas' Hospital, Rigshospitalet, Hospital Clínic de Barcelona, and research institutes including Institut Curie, Max Delbrück Center for Molecular Medicine, Francis Crick Institute, and Institute of Human Genetics (Poland). Membership includes national reference laboratories, university diagnostic services, commercial diagnostic companies like QIAGEN, Roche Diagnostics, Abbott Laboratories, and biotechnology firms informed by developments at Genentech, Illumina, Thermo Fisher Scientific, and Sanger Institute spinouts. The Network engages with patient groups and advocacy organizations such as European Patients' Forum, Genetic Alliance UK, EURORDIS, and disease-specific charities linked to Cystic Fibrosis Trust, SMA Europe, and Cancer Research UK to ensure clinical relevance.

Proficiency testing schemes cover sequence analysis, copy-number variation, methylation assays, somatic mutation detection, and pharmacogenetic genotyping, reflecting technologies from Sanger sequencing, next-generation sequencing, array comparative genomic hybridization, polymerase chain reaction, and digital PCR. Programs assess performance using reference materials developed in collaboration with National Institute for Biological Standards and Control, European Reference Networks, Centers for Disease Control and Prevention, and biobanks such as UK Biobank and Biobank Japan. External quality assessment exercises are designed in consultation with specialty groups including European Society for Medical Oncology, European Haematology Association, International Society for Prenatal Diagnosis, and European Society of Human Genetics Education Committee.

The Network’s activities map to international standards including ISO/IEC 17043, ISO 15189, and guidance from European Directorate for the Quality of Medicines & HealthCare and Council of Europe Directorate. It collaborates with accreditation bodies such as United Kingdom Accreditation Service, Deutsche Akkreditierungsstelle, COFRAC, Akkreditierungsgesellschaft für Medizinische Labore, and national accreditation agencies to support laboratory accreditation pathways. The Network contributes to consensus documents and technical reports together with European Society of Human Genetics, World Health Organization, International Organization for Standardization technical committees, and specialist working groups from European Molecular Biology Laboratory and European Reference Networks.

Educational activities include workshops, webinars, and hands-on courses developed with academic partners like University of Edinburgh, University of Heidelberg, Trinity College Dublin, University of Zurich, and University of Milan. Training topics cover analytic validation, bioinformatics pipelines informed by tools from European Bioinformatics Institute, Genome Analysis Toolkit developers, and variant interpretation frameworks aligned with recommendations from American College of Medical Genetics and Genomics, ClinGen, and the Human Variome Project. Continuing professional development credits are coordinated with professional bodies including Royal College of Pathologists, German Society of Human Genetics, French Society of Human Genetics, and European Federation of Clinical Chemistry and Laboratory Medicine.

Governance involves a steering committee, scientific advisory board, and operational secretariat drawing expertise from institutions such as European Society of Human Genetics, European Molecular Biology Laboratory, European Commission, World Health Organization, and national ministries of health. Funding sources combine participation fees, grants from organizations like European Commission Horizon 2020, European Regional Development Fund, philanthropic support from foundations such as Wellcome Trust and Bill & Melinda Gates Foundation, and partnerships with industry players including Illumina, Roche, and QIAGEN. Annual reports and strategic plans are developed in consultation with stakeholders including patient advocacy groups, academic centers, accreditation bodies, and national competent authorities to align priorities with evolving diagnostic needs.

Category:Medical and health organizations